NCOA7 Antibody

What is NCOA7 and why is it an important research target?

NCOA7, also known as nuclear receptor coactivator 7, is a 942 amino acid nuclear protein with a molecular mass of 106.2 kDa in its canonical form . This protein belongs to the OXR1 family and plays crucial roles in oxidative stress response and transcriptional regulation . NCOA7 has gained research importance due to its demonstrated role as a V-ATPase regulatory protein in the brain, where it modulates lysosomal function, neuronal connectivity, and behavior . The protein is highly expressed in brain tissue, with lower expression levels detected in the pancreas, bladder, ovary, spinal cord, prostate, mammary gland, uterus, and stomach, highlighting its widespread physiological importance . As a multifunctional protein involved in both nuclear receptor signaling and cellular stress responses, NCOA7 represents a valuable target for understanding fundamental cellular processes and potential therapeutic interventions.

What are the common applications for NCOA7 antibodies in research?

NCOA7 antibodies are utilized in multiple experimental techniques for detecting and studying this protein. The most common applications include:

• Western Blotting (WB): The primary method for detecting NCOA7 protein expression and quantifying relative abundance in tissue or cell lysates .

• Immunoprecipitation (IP): Used to isolate NCOA7 and its binding partners to study protein-protein interactions, particularly with nuclear receptors and V-ATPase components .

• Immunofluorescence (IF): Enables visualization of NCOA7 subcellular localization, confirming its nuclear distribution and potential translocation under different conditions .

• Enzyme-Linked Immunosorbent Assay (ELISA): Provides quantitative measurement of NCOA7 protein levels in various sample types .

• Immunohistochemistry (IHC): Allows researchers to examine NCOA7 expression patterns in tissue sections, particularly useful for brain research where NCOA7 shows high expression .

These diverse applications make NCOA7 antibodies versatile tools for investigating both the expression patterns and functional aspects of this protein across different experimental contexts.

How should I select the appropriate NCOA7 antibody for my research?

When selecting an NCOA7 antibody, consider these critical factors:

• Isoform specificity: NCOA7 exists in up to 7 different isoforms, with the short NCOA7-B isoform containing only the TLDc domain . Determine which isoform(s) you need to detect based on your research question. Full-length antibodies target the canonical 942 amino acid protein, while others may be specific to particular isoforms or domains.

• Species reactivity: Confirm the antibody's reactivity with your species of interest. Many commercially available NCOA7 antibodies detect human, mouse, and rat proteins, but cross-reactivity varies . NCOA7 orthologs have been reported in mouse, rat, bovine, frog, chimpanzee, and chicken species .

• Application compatibility: Verify the antibody has been validated for your specific application. Some antibodies perform well in Western blotting but may not be suitable for immunohistochemistry or immunofluorescence .

• Epitope location: Consider which region of NCOA7 the antibody recognizes. Antibodies targeting different domains (LysM repeat, TLD domain) may yield different results depending on protein conformation or interaction status .

• Conjugation requirements: Determine if you need a conjugated antibody. NCOA7 antibodies are available in unconjugated forms or conjugated to various molecules including biotin, HRP, PE, FITC, and Alexa Fluor dyes for different detection methods .

Thorough validation using positive and negative controls is essential before proceeding with extensive experiments to ensure specificity and sensitivity for your particular experimental system.

How can NCOA7 antibodies be used to investigate its role in V-ATPase regulation?

NCOA7 antibodies can be strategically employed to examine the protein's critical role in V-ATPase regulation through several advanced techniques:

• Co-immunoprecipitation (Co-IP): Using NCOA7 antibodies for Co-IP followed by mass spectrometry or western blotting can identify and validate interactions with V-ATPase subunits. Research has shown that NCOA7 binds to the cytoplasmic V1 domain of the V-ATPase, specifically interacting with several subunits including ATP6V1B2 and ATP6V1C that are critical for proper V1 complex formation .

• Proximity ligation assays (PLA): This technique can visualize the physical proximity between NCOA7 and V-ATPase components in situ, providing spatial information about their interaction within cellular compartments.

• Subcellular fractionation with immunoblotting: By separating cellular components and performing western blotting with NCOA7 antibodies, researchers can track the distribution of NCOA7 between cytosolic and membrane fractions. This approach has revealed that NCOA7 deletion causes a significant shift in the distribution of ATP6V1B2 and ATP6V1A1 subunits away from the membrane in neurons .

• Lysosomal function assays: Following NCOA7 knockdown or knockout, antibodies can be used to assess changes in lysosomal marker proteins, helping to characterize the functional consequences of disrupted V-ATPase regulation. Studies have demonstrated that absence of NCOA7 negatively affects lysosomal physiology, resulting in cytosolic accumulation of potentially undegraded material in neurons .

These approaches collectively provide mechanistic insights into how NCOA7 modulates V-ATPase assembly and functionality in the brain, with implications for understanding neurological disorders associated with lysosomal dysfunction .

What experimental approaches can detect the different NCOA7 isoforms?

Detecting and distinguishing between multiple NCOA7 isoforms requires careful experimental design:

• Isoform-specific antibodies: Select antibodies raised against unique regions of specific isoforms. For instance, antibodies targeting the unique first exon of NCOA7-B can selectively detect this short isoform that contains only the TLDc domain . Similarly, antibodies against N-terminal regions absent in shorter isoforms can identify full-length variants.

• RT-PCR with isoform-specific primers: Design primers that span unique exon junctions or target isoform-specific sequences. This approach was successfully used to confirm the absence of all NCOA7 isoforms in the DEL mouse model .

• Western blotting with gradient gels: Use gradient polyacrylamide gels to achieve better separation of proteins with different molecular weights. The canonical NCOA7 isoform has a mass of 106.2 kDa, while other isoforms have distinct sizes that can be resolved with appropriate gel conditions .

• Mass spectrometry: Employ proteomics approaches to identify unique peptide sequences corresponding to different isoforms. This technique can provide unambiguous identification of specific isoforms present in a sample.

• In situ hybridization with isoform-specific probes: For tissue-specific expression analysis, design RNA probes that hybridize to unique regions of different isoforms. This technique has been used to demonstrate the widespread expression of NCOA7 in major brain regions from embryonic stages into adulthood .

The choice of detection method should be guided by the specific research question. When investigating isoform-specific functions, it's crucial to validate the specificity of the detection method using appropriate controls, such as knockout models lacking specific isoforms or overexpression systems with verified isoform identity .

How can NCOA7 antibodies help elucidate its role in oxidative stress response pathways?

NCOA7 antibodies can be instrumental in investigating the protein's involvement in oxidative stress response through several sophisticated approaches:

• Chromatin immunoprecipitation (ChIP): Using NCOA7 antibodies for ChIP experiments can identify genomic binding sites and target genes regulated by NCOA7 during oxidative stress. As a member of the OXR1 protein family involved in oxidative stress response, NCOA7 likely influences the transcription of genes related to cellular protection mechanisms .

• Phosphorylation-specific antibodies: Develop or obtain antibodies that recognize post-translationally modified forms of NCOA7 that may emerge during oxidative stress response. These modifications often regulate protein activity or interactions in stress conditions.

• Co-localization studies: Combine NCOA7 antibodies with markers of cellular stress response pathways in immunofluorescence experiments to track dynamic changes in NCOA7 localization and protein interactions during oxidative stress.

• Proximity-dependent biotin identification (BioID): Fuse NCOA7 to a biotin ligase and use antibodies to analyze the changing interactome of NCOA7 under normal versus oxidative stress conditions, revealing stress-specific protein associations.

• Time-course immunoprecipitation: Apply NCOA7 antibodies to capture the protein at different time points following oxidative insult, followed by mass spectrometry to identify dynamic changes in binding partners throughout the stress response.

These approaches can reveal the molecular mechanisms through which NCOA7 contributes to cellular protection against oxidative damage, potentially informing therapeutic strategies for conditions associated with oxidative stress, including neurodegenerative diseases where NCOA7 is abundantly expressed .

What are the key validation steps for NCOA7 antibodies in experimental protocols?

Proper validation of NCOA7 antibodies is crucial for ensuring experimental reliability and reproducibility:

• Specificity testing using knockout/knockdown models: The gold standard for antibody validation is testing against samples where the target protein is absent. Researchers have generated NCOA7 knockout mouse models using CRISPR-Cas9 to delete the entire coding region, creating valuable negative controls for antibody validation . When using these models, Western blotting confirmed the absence of all NCOA7 isoforms in DEL tissue, verifying antibody specificity .

• Cross-reactivity assessment: Test the antibody against related proteins, particularly other TLDc domain-containing proteins like OXR1, to confirm specificity. This is especially important given the structural similarities and potential functional redundancy between family members .

• Multiple detection methods: Validate the antibody using different applications (Western blot, immunohistochemistry, immunofluorescence) to confirm consistent detection patterns across techniques .

• Preabsorption tests: Incubate the antibody with purified NCOA7 protein prior to immunostaining or immunoblotting. This should eliminate specific staining if the antibody is truly specific for NCOA7.

• Correlation between protein and mRNA expression: Compare antibody staining patterns with mRNA expression data from in situ hybridization or transcriptomic analysis to ensure concordance between protein detection and gene expression .

• Epitope mapping: Determine which region of NCOA7 the antibody recognizes, particularly important when studying specific isoforms or domains. For instance, antibodies targeting the TLDc domain would detect both full-length NCOA7 and the shorter NCOA7-B isoform .

These rigorous validation steps help mitigate the risk of false-positive or non-specific results, ensuring that experimental findings accurately reflect NCOA7 biology.

How should researchers optimize immunofluorescence protocols for NCOA7 detection in different tissue types?

Optimizing immunofluorescence protocols for NCOA7 detection requires tissue-specific considerations:

• Fixation optimization: For brain tissues where NCOA7 is highly expressed, 4% paraformaldehyde is typically effective, but fixation time should be optimized based on tissue thickness . For other tissues with lower expression (pancreas, ovary, prostate), shorter fixation times may preserve epitope accessibility.

• Antigen retrieval methods: Test multiple antigen retrieval approaches:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0)

  • Enzymatic retrieval with proteinase K (for heavily fixed tissues)

  • Tris-EDTA buffer (pH 9.0) for tissues with high lipid content

• Blocking optimization: For brain tissues, include both serum (5-10%) and bovine serum albumin (3-5%) in blocking solutions to reduce non-specific binding. Consider adding 0.1-0.3% Triton X-100 for better antibody penetration in tissues with high lipid content.

• Signal amplification strategies: For tissues with lower NCOA7 expression, employ tyramide signal amplification (TSA) or use highly sensitive detection systems like Alexa Fluor 647-conjugated secondary antibodies which provide better signal-to-noise ratios .

• Co-staining considerations: When performing co-localization studies, particularly with V-ATPase components or lysosomal markers, carefully select antibodies raised in different host species to avoid cross-reactivity. This is essential when investigating NCOA7's role in lysosomal function and V-ATPase regulation .

• Confocal imaging parameters: Use appropriate laser power and gain settings to detect nuclear NCOA7 without saturating the signal. Z-stack imaging is recommended to capture the three-dimensional distribution of NCOA7, particularly important when examining its association with membrane structures like lysosomes .

The protocol should be systematically optimized for each tissue type, with particular attention to the subcellular localization pattern expected (primarily nuclear for NCOA7) .

What considerations should be made when designing experiments to study NCOA7 in the context of lysosomal function?

When investigating NCOA7's role in lysosomal function, researchers should consider these experimental design factors:

• Appropriate cellular models: Select cell types where NCOA7-dependent lysosomal phenotypes have been documented. Neuronal models are particularly relevant given NCOA7's high expression in the brain and its established role in neuronal lysosomal function . Primary neurons from NCOA7 knockout models have demonstrated accumulation of undegraded material, providing a useful experimental system .

• Lysosomal function assays: Implement multiple complementary approaches:

  • Lysosomal pH measurement using ratiometric probes

  • Cathepsin activity assays to assess lysosomal enzyme function

  • Autophagy flux monitoring with LC3 conversion assays

  • Lysosomal morphology assessment using LAMP1/2 immunostaining

  • Lysosomal stress markers (e.g., TFEB nuclear translocation)

• V-ATPase assembly analysis: Given NCOA7's role in V-ATPase regulation, assess V-ATPase assembly status through:

  • Subcellular fractionation to examine membrane association of V-ATPase subunits

  • Co-immunoprecipitation to analyze V-ATPase complex formation

  • Proximity ligation assays to visualize interactions between V-ATPase subunits

• Rescue experiments: Include experimental conditions where NCOA7 is reintroduced to knockout/knockdown systems. Research has demonstrated that defects in lysosomal homeostasis caused by deletion of NCOA7 can be rescued by exogenous replacement of the protein, providing important causality evidence .

• Stress conditions: Examine lysosomal function under both basal and stressed conditions (e.g., oxidative stress, starvation), as NCOA7's role may be particularly important during cellular stress responses .

• Temporal considerations: Design time-course experiments to distinguish between acute versus chronic effects of NCOA7 deficiency on lysosomal function, which may reveal different mechanisms of action.

These considerations help establish a comprehensive experimental approach to elucidating NCOA7's specific contributions to lysosomal physiology, particularly through its regulation of V-ATPase assembly and function .

What are common problems encountered when using NCOA7 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with NCOA7 antibodies, with corresponding solutions:

• High background signal in immunostaining:

  • Problem: Non-specific binding causing diffuse background staining.

  • Solution: Increase blocking time (2-4 hours) using 5% BSA with 0.3% Triton X-100. Use antibody concentrations optimized through titration experiments. Consider adding 5% serum from the same species as the secondary antibody to reduce non-specific binding .

• Weak or absent signal in Western blotting:

  • Problem: Insufficient protein extraction or epitope masking.

  • Solution: For nuclear proteins like NCOA7, use RIPA buffer supplemented with benzonase for efficient nuclear protein extraction. Longer transfer times (overnight at low voltage) may be necessary for the 106.2 kDa NCOA7 protein. Ensure sufficient protein loading (50-100 μg for tissue lysates) .

• Multiple bands in Western blots:

  • Problem: Detection of multiple isoforms or degradation products.

  • Solution: Verify band patterns against known molecular weights of NCOA7 isoforms (canonical protein is 106.2 kDa). Use freshly prepared samples with complete protease inhibitor cocktails. Compare results with NCOA7 knockout controls to distinguish specific from non-specific bands .

• Inconsistent immunoprecipitation results:

  • Problem: Poor antibody binding efficiency or harsh elution conditions.

  • Solution: Consider using antibody-conjugated agarose beads for more efficient capture . Optimize salt concentration in wash buffers (150-300 mM NaCl) to balance specificity with binding strength. Use gentle elution methods (competitive epitope peptides rather than boiling in SDS) to preserve protein interactions.

• Cross-reactivity with other TLDc domain proteins:

  • Problem: Antibodies recognizing conserved regions may cross-react with related proteins.

  • Solution: Select antibodies raised against unique regions of NCOA7 rather than the conserved TLDc domain. Validate specificity using tissues from NCOA7 knockout models alongside wild-type controls .

These troubleshooting approaches ensure more reliable and reproducible results when using NCOA7 antibodies across different experimental applications.

How can researchers reconcile conflicting results from different NCOA7 antibodies?

When faced with discrepancies between results obtained using different NCOA7 antibodies, researchers should follow this systematic reconciliation approach:

• Epitope mapping analysis: Determine the specific epitopes recognized by each antibody. Antibodies targeting different domains of NCOA7 (such as the N-terminal region versus the TLDc domain) may yield different results depending on protein conformation, post-translational modifications, or interactions with other proteins .

• Isoform specificity assessment: Verify which NCOA7 isoforms each antibody detects. With up to 7 different isoforms reported, antibodies may have variable specificity for different variants . For instance, antibodies targeting the unique first exon of NCOA7-B will detect only this short isoform, while antibodies against regions common to all isoforms will detect multiple proteins .

• Validation using genetic models: Test all antibodies against samples from NCOA7 knockout models. The complete NCOA7 deletion model (DEL) lacking all isoforms provides an ideal negative control to evaluate antibody specificity . Western blotting, in situ hybridization, and immunostaining with DEL tissues have confirmed the absence of all NCOA7 isoforms and can help identify truly specific antibodies .

• Cross-validation with orthogonal techniques: Compare antibody-based results with orthogonal approaches:

  • mRNA expression (RT-PCR or RNA-seq)

  • Tagged overexpression systems

  • Mass spectrometry-based protein identification

• Experimental condition differences: Evaluate whether discrepancies arise from differences in:

  • Sample preparation methods (fixation, protein extraction)

  • Detection systems (chromogenic vs. fluorescent)

  • Cellular states (stress conditions may affect epitope accessibility)

• Antibody validation status: Review the validation data for each antibody, prioritizing results from antibodies with more extensive validation across multiple applications and sample types .

When reporting results, transparently document which antibody was used and its validation status, enabling more accurate comparison and interpretation across studies in the field.

What approaches can resolve difficulties in detecting endogenous NCOA7 in cells with low expression levels?

Detecting endogenous NCOA7 in cells with low expression presents significant challenges that can be addressed through these specialized approaches:

• Signal amplification techniques:

  • Tyramide signal amplification (TSA): This enzymatic amplification method can increase signal intensity 10-100 fold for immunohistochemistry and immunofluorescence applications.

  • Poly-HRP secondary antibodies: These contain multiple HRP molecules per antibody, significantly enhancing chemiluminescent signal in Western blotting.

  • Rolling circle amplification (RCA): For in situ applications, RCA can dramatically increase detection sensitivity for low-abundance proteins.

• Enrichment strategies:

  • Nuclear fraction isolation: Since NCOA7 is primarily nuclear , isolating nuclear fractions concentrates the protein relative to total cell lysates.

  • Immunoprecipitation before Western blotting: Use NCOA7 antibodies to pull down and concentrate the protein before detection, particularly effective with antibody-conjugated agarose beads .

• Enhanced detection systems:

  • Highly sensitive ECL substrates: Super-signal femto or similar reagents can detect proteins in the low picogram range.

  • Cooled CCD camera imaging: For Western blots, longer exposure times with cooled CCD cameras can detect signals not visible with standard film exposure.

  • Confocal microscopy with spectral unmixing: Helps distinguish true NCOA7 signal from autofluorescence in tissues with high background.

• Protein stabilization approaches:

  • Proteasome inhibitors (MG132): Brief treatment before sample collection can increase detection of proteins with high turnover rates.

  • Deacetylase inhibitors: May enhance detection if acetylation affects NCOA7 stability.

• Context-specific upregulation:

  • IFN treatment: The short NCOA7-B isoform is activated via interferon-mediated pathways, so IFN treatment before analysis can increase expression levels for detection .

  • Oxidative stress induction: As an oxidative stress response protein, NCOA7 levels may increase following appropriate stress stimuli .

• Single-cell analysis techniques:

  • RNA-FISH combined with immunofluorescence: Can correlate mRNA and protein expression at the single-cell level, helping identify cells with detectable NCOA7 expression within heterogeneous populations.

These approaches can be combined or sequentially implemented to achieve successful detection of endogenous NCOA7 even in systems with naturally low expression levels.

How might new antibody technologies advance our understanding of NCOA7 function?

Emerging antibody technologies offer promising avenues for deeper exploration of NCOA7 biology:

• Domain-specific nanobodies: Single-domain antibodies derived from camelid species can access epitopes unavailable to conventional antibodies due to their small size. Developing nanobodies against specific NCOA7 domains could enable better discrimination between isoforms and improved access to epitopes in complex protein assemblies, particularly valuable for studying NCOA7's interactions with V-ATPase components .

• Intrabodies with subcellular targeting: Genetically encoded antibody fragments that function within living cells can be modified to track NCOA7 in real-time. These could be targeted to specific subcellular compartments (nucleus, lysosomes) to monitor NCOA7 trafficking and interactions during cellular processes like lysosomal acidification or stress responses .

• Proximity-dependent labeling antibodies: Antibodies conjugated to enzymes like APEX2 or TurboID can biotinylate proteins in close proximity to NCOA7, providing dynamic interactome mapping under various cellular conditions. This approach could reveal transient NCOA7 interactions during V-ATPase assembly or disassembly that are difficult to capture with traditional immunoprecipitation .

• Conformation-specific antibodies: Developing antibodies that recognize specific structural states of NCOA7 could distinguish between active and inactive forms or identify conformational changes induced by protein interactions or post-translational modifications.

• Multiplexed imaging antibodies: DNA-barcoded antibodies or metal-tagged antibodies for imaging mass cytometry could enable simultaneous visualization of NCOA7 alongside dozens of other proteins. This would facilitate comprehensive mapping of NCOA7's relationships with components of oxidative stress response pathways and lysosomal machinery .

• Cleavable crosslinking antibodies: These emerging tools can capture weak or transient protein interactions through crosslinking, followed by controlled release for analysis. They could help elucidate NCOA7's dynamic interactions during stress responses or its association with the V-ATPase during assembly/disassembly cycles .

These technological advances promise to reveal new aspects of NCOA7 biology, particularly its dynamic behavior and context-specific functions across different cellular compartments and physiological states.

What are the implications of recent NCOA7 research for understanding neurodegenerative diseases?

Recent discoveries about NCOA7 function have significant implications for neurodegenerative disease research:

• Lysosomal dysfunction connection: NCOA7's role in regulating V-ATPase assembly and lysosomal function provides a mechanistic link to neurodegenerative diseases . Many neurodegenerative conditions, including Parkinson's, Alzheimer's, and lysosomal storage disorders, involve impaired lysosomal function and protein degradation. NCOA7 antibodies could help characterize lysosomal abnormalities in disease models and patient samples.

• Oxidative stress protection: As a member of the OXR1 protein family involved in oxidative stress response, NCOA7 may contribute to neuroprotection . Oxidative damage is a common feature across neurodegenerative diseases, and understanding how NCOA7 mediates cellular protection could reveal new therapeutic strategies.

• Brain-specific expression patterns: NCOA7's high expression in the brain, demonstrated through in situ hybridization studies from embryonic stages into adulthood, suggests specialized neuronal functions . Region-specific analysis using NCOA7 antibodies could identify vulnerable neuronal populations in disease states.

• V-ATPase regulation and neuronal connectivity: Research using NCOA7 knockout models revealed that NCOA7 modulates not only lysosomal function but also neuronal connectivity and behavior . These findings suggest NCOA7 dysfunction could contribute to neural circuit abnormalities observed in neurodegenerative and neurodevelopmental disorders.

• Potential compensatory mechanisms: Studies with the NCOA7 deletion model showed less severe phenotypes than might be expected, possibly due to compensation by related proteins like OXR1 . Understanding these compensatory mechanisms using isoform-specific antibodies could reveal new therapeutic targets for boosting cellular resilience.

• Interference with lipid homeostasis: NCOA7 deficiency leads to sterol accumulation and production of oxysterol species through cholesterol 25-hydroxylase (CH25H) . Lipid dysregulation is increasingly recognized as an important factor in various neurodegenerative diseases, making NCOA7's role in lipid metabolism particularly relevant.

These connections highlight the value of NCOA7 antibodies as tools for investigating fundamental disease mechanisms and potentially identifying new therapeutic approaches for neurodegenerative conditions.

How might NCOA7 antibodies contribute to translational research in inflammatory and vascular diseases?

NCOA7 antibodies have significant potential to advance translational research in inflammatory and vascular diseases:

• Allele-specific expression analysis: Transcriptomic analysis has linked an allelic variant at SNP rs11154337 in NCOA7 with metabolic phenotypes relevant to vascular disease . Antibodies could help determine whether this variant affects protein expression levels or patterns in vascular tissues, enabling genotype-phenotype correlation studies.

• NF-κB signaling intersection: Proinflammatory stimuli integrate onto NF-κB to control NCOA7 expression in an allele-specific manner . NCOA7 antibodies could track how different inflammatory stimuli modulate NCOA7 levels and subcellular localization in vascular cells, providing insights into inflammatory signaling mechanisms.

• Endothelial activation monitoring: Research has shown that NCOA7 deficiency leads to immunoactivation of the endothelium with increased vascular cell adhesion molecule 1 (VCAM1) expression and immune cell attachment . Antibodies targeting NCOA7 alongside endothelial activation markers could help stratify patients according to their inflammatory endothelial phenotype.

• Sterol metabolism pathways: NCOA7 knockdown results in lysosomal dysfunction and sterol accumulation, leading to production of oxysterol species through cholesterol 25-hydroxylase (CH25H) . Antibodies against NCOA7 and related metabolic enzymes could help characterize this pathway in vascular disease samples and identify potential intervention points.

• Angiogenesis research: In an angioproliferative mouse model, loss of NCOA7 worsened hemodynamic indices of disease . NCOA7 antibodies could be used to study protein expression patterns in angiogenic vessels and correlate with disease progression markers.

• Biomarker development: Changes in NCOA7 expression or localization might serve as biomarkers for vascular dysfunction or inflammatory status. Validated antibodies could enable the development of tissue or circulating biomarker assays with clinical utility.